Firm names are the property of their respective owners and appear here for identification in news reporting, without affiliation or endorsement.
Firm Wire items are announcements made by the firms themselves. The desk confirms that the announcement was published and reproduces its factual content. It does not verify the claims in it, and publication is not an endorsement.
Choate said it represented initial purchasers in NSTAR Gas Company’s $100 million private placement of first mortgage bonds. The firm said NSTAR Gas does business as Eversource Energy and identified the transaction as an offering of Series AA bonds due in 2036.
Choate said it received a highly recommended designation for dispute resolution, life sciences and technology patent law in Massachusetts in Benchmark Litigation’s 2027 survey. The firm said several attorneys were recognized in multiple categories and described the research as drawing on interviews with litigators, specialists and clients.
Choate said it advised longtime client Merida Biosciences on its acquisition by Eli Lilly and Company in a transaction valued at up to $2.875 billion. The firm said Merida develops precision autoantibody degraders intended to treat autoimmune and allergic diseases and identified its intellectual property team supporting the deal.
Choate said it represented Treville Capital Group as lead investor in a $355 million growth financing for Platform Accounting Group. The firm said the financing supports the accounting business’s acquisition strategy, expansion of services and investment in technology and personnel across its operations.
Choate said its 2026 summer associates ranked the firm among the top five nationally in The American Lawyer’s Summer Associate Satisfaction Survey. The firm said the survey polled more than 2,000 summer associates at 49 law firms and used scores supplied by those participants.
Choate said Margo Monroe and Mandeep Kaur will speak at the Oncology Venture, Innovation & Partnering Summit on October 20. The firm said they will join a panel examining intellectual property findings that change valuation, within a session addressing diligence, clinical trials and exclusivity.